Drug updated on 9/4/2024
Dosage Form | Capsule (oral; 80 mg) |
Drug Class | Transthyretin stabilizers |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Latest News
Summary
- Vyndaqel (tafamidis meglumine) is indicated for the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
- This summary is based on the review of eight systematic review(s)/meta-analysis(es). [1-8]
- Tafamidis significantly reduced cardiovascular mortality in the ATTR-ACT trial (OR 0.58; 95% CI: [0.41-0.83], P=0.003) and all-cause mortality (OR 0.45; 95% CI: [0.32-0.64], P≤0.00001).
- Tafamidis treatment was associated with a reduced risk of all-cause death or heart transplantation (pooled RR 0.44; 95% CI: [0.31-0.65], P<0.01) and composite cardiovascular endpoints (RR 0.57; 95% CI: [0.42-0.77], P<0.01).
- Tafamidis showed a decrease in Left Ventricular Ejection Fraction (LVEF) (SMD -0.17; 95% CI: [-0.31 to -0.03]; P=0.02), with no significant LVEF deterioration in wild-type ATTR patients (SMD -0.11; 95% CI: [-0.34 to 0.12]; P=0.34).
- No clear difference between groups in the number of participants who died, dropped out due to adverse events, or experienced at least one severe adverse event compared to placebo.
- Tafamidis might lead to little or no difference in mortality (RR 0.65, 95% CI 0.11 to 3.74; P=0.63; very low-certainty evidence).
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Vyndaqel (tafamidis meglumine) Prescribing Information. | 2023 | Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. | 2020 | Circulation Journal |
CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. | 2020 | Canadian Journal of Cardiology |
Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. | 2020 | Canadian Cardiovascular Society |
Cardiac amyloidosis: evolving diagnosis and management. | 2020 | American Heart Association |